Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) CEO Jeffrey Dayno sold 25,933 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a document filed with the SEC, which is available

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) were down 3.9% on Thursday following insider selling activity. The stock traded as low as $37.47 and last traded at $37.2550. Approximately 120,139 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 729,320 shares. The stock had

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for rare neurological disorders, to incorporate quantitative electroencephalography (EEG) measurements into two of Harmony's Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. The collaboration will support Harmony's primary objective of assessing excessive daytime sleepiness (EDS) by complementing traditional patient-reported outcomes, such as the Epworth Sleepiness Scale (ESS), with objective sleep EEG data.

Federated Hermes Inc. cut its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 33.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 293,842 shares of the company's stock after selling 146,042 shares during the period. Federated Hermes

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company's ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome (DS), which showed clinically meaningful reductions in seizure activity in participants with DS along with a favorable benefit-risk profile. The data from poster #3.353 will be presented at the Americ.

Capital Fund Management S.A. bought a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 36,147 shares of the company's stock, valued at approximately $1,142,000. Capital Fund Management S.A. owned

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA. The ARGUS trial is currently enrolling, and more information can be found at arg.

Boston Partners purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 605,495 shares of the company's stock, valued at approximately $19,398,000. Boston Partners owned approximately 1.05% of

American Century Companies Inc. grew its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 16.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,501,420 shares of the company's stock after buying an additional 212,633 shares during the period. American Century Companies Inc. owned 2.61%

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant gastro-resistant (GR) formulation. With positive findings from both the pivotal BE and dosing optimization studies, Harmony is on track to submit a New Drug Application (NDA) for pitolisant GR in early 2026, targeting a PDUFA date in Q1 2027. With utility patent applications filed for pitolisant GR with potent.